Fill-finish Pharmaceutical Contract Market Global outlook 2024 to 2031 | Skyquest Leading market research firm SkyQuest Technology Group recently released a study titled 'Fill-finish Pharmaceutical Contract Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Fill-finish Pharmaceutical Contract report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Fill-finish Pharmaceutical Contract Market extensively demonstrates existing and upcoming opportunities, profitability, revenue growth rates, pricing, and scenarios for recent industry analysis. The research analysis on the global Fill-finish Pharmaceutical Contract Market report 2024 offers a close watch on top industry rivals along with briefings on their company profiles, strategical surveys, micro as well as macro industry trends, futuristic scenarios, analysis of pricing structure, and an all-encompassing overview of the Fill-finish Pharmaceutical Contract Market circumstances in the forecast period between 2024 and 2031. The global Fill-finish Pharmaceutical Contract Market is a dynamic and rapidly evolving sector, encompassing the development, production, and distribution. This market is essential for improving global market and driving economic growth through innovation and industry advancements. Market Growth The Fill-finish Pharmaceutical Contract Market has experienced robust growth over the past decade and is projected to continue expanding. In 2022, the global fill-finish pharmaceutical contract manufacturing market reached a significant value of USD 8.1 billion. Projections indicate that this market is poised for steady growth, with an estimated compound annual growth rate (CAGR) of 6.1% expected from 2024 to 2031. This growth is driven by several factors, including an aging global population, increasing prevalence of advancements in technology, and rising global expenditure. Chance to get a free sample @ https://www.skyquestt.com/sample-request/fill-finish-pharmaceutical-contract-manufacturing-market Detailed Segmentation and Classification of the report (Market Size and Forecast - 2031, Y-o-Y growth rate, and CAGR): The Fill-finish Pharmaceutical Contract Market can be segmented based on several factors, including product type, application, end-user, and distribution channel. Understanding these segments is crucial for companies looking to target specific markets and tailor their offerings to meet consumer needs. By Product Type - Prefilled Syringes, Vials, Cartridges, Others By Molecule Type - Large Molecules, Small Molecules By End-user - Biopharmaceutical Companies, Pharmaceutical Companies By Region - North America, Asia Pacific, Latin America, Europe Get your customized report @ https://www.skyquestt.com/speak-with-analyst/fill-finish-pharmaceutical-contract-manufacturing-market Following are the players analyzed in the report: AbbVie Inc. Boehringer Ingelheim Pfizer Catalent Inc Recro Pharma, Inc. Baxter’s BioPharma Solutions Eurofins Scientific Symbiosis Pharmaceutical Service MabPlex International Co. Ltd. Recipharm AB Fresenius Kabi Contract Manufacturing Novartis Regional Analysis 1. North America: - The United States and Canada dominate the North American Fill-finish Pharmaceutical Contract Market. The U.S. is the largest market globally, driven by advanced global infrastructure, high R&D investments, and significant Fill-finish Pharmaceutical Contract consumption. 2. Europe: - Europe is a significant player, with major Fill-finish Pharmaceutical Contract Markets in Germany, France, and the United Kingdom. The region benefits from strong regulatory frameworks, high industry standards, and a robust R&D sector. 3. Asia-Pacific: - This region is experiencing rapid growth, with countries like China and India leading the charge. Factors such as increasing industry access, growing middle-class populations, and expanding Fill-finish Pharmaceutical Contract manufacturing capabilities contribute to this growth. 4. Latin America: - Brazil and Mexico are key markets in Latin America. Growth in this region is driven by rising industry needs, increasing investments in industry infrastructure, and a growing demand for affordable medications. 5. Middle East and Africa: - The Fill-finish Pharmaceutical Contract Market in this region is expanding due to rising market spending, increased prevalence of diseases, and improvements in Market infrastructure, although the market is relatively smaller compared to other regions. Future Outlook The Fill-finish Pharmaceutical Contract Market is poised for continued growth driven by technological advancements, expanding global market access, and increasing global industry needs. As the industry adapts to evolving challenges and seizes emerging opportunities, it is likely to see ongoing innovation and expansion, contributing significantly to global health and economic development. Buy your full report: https://www.skyquestt.com/buy-now/fill-finish-pharmaceutical-contract-manufacturing-market

Cartilage Repair Market Global Latest Trends and Insights 2024 to 2031 Leading market research firm SkyQuest Technology Group recently released a study titled ‘Cartilage Repair Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024–2031,’ This study Cartilage Repair report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Cartilage Repair Market extensively demonstrates existing and upcoming opportunities, profitability, revenue growth rates, pricing, and scenarios for recent industry analysis. The research analysis on the global Cartilage Repair Market report 2024 offers a close watch on top industry rivals along with briefings on their company profiles, strategical surveys, micro as well as macro industry trends, futuristic scenarios, analysis of pricing structure, and an all-encompassing overview of the Cartilage Repair Market circumstances in the forecast period between 2024 and 2031. The global Cartilage Repair Market is a dynamic and rapidly evolving sector, encompassing the development, production, and distribution. This market is essential for improving global market and driving economic growth through innovation and industry advancements. Market Growth The Cartilage Repair Market has experienced robust growth over the past decade and is projected to continue expanding. Cartilage Repair Market size was valued at USD 927.63 million in 2022 and is poised to grow from USD 1040.29 million in 2023 to USD 1570.16 million by 2031, growing at a CAGR of 12.13% in the forecast period (2024–2031). This growth is driven by several factors, including an aging global population, increasing prevalence of advancements in technology, and rising global expenditure. Chance to get a free sample @ https://www.skyquestt.com/sample-request/cartilage-repair-market Detailed Segmentation and Classification of the report (Market Size and Forecast — 2031, Y-o-Y growth rate, and CAGR): The Cartilage Repair Market can be segmented based on several factors, including product type, application, end-user, and distribution channel. Understanding these segments is crucial for companies looking to target specific markets and tailor their offerings to meet consumer needs. Treatment modality type Cell-Based (Chondrocyte Transplantation, Growth Factor Technology), Non-Cell-Based (Tissue Scaffolds, Cell-Free Composites) Application Hyaline, Fibrocartilage Treatment type Palliative (Viscosupplementation, Debridement & Lavage), Intrinsic Repair Stimulus Site Knee Cartilage Repair (Arthroscopic Chondroplasty, Autologous Chondrocyte, Osteochondral Grafts Transplantation, Cell-based Cartilage Resurfacing, Microfracture, Other), Other Regional Analysis: On the basis of region, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The Cartilage Repair Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications. Get your customized report @ https://www.skyquestt.com/speak-with-analyst/cartilage-repair-market Following are the players analyzed in the report: DePuy Synthes (a subsidiary of Johnson & Johnson) Zimmer Biomet Holdings Inc. Smith & Nephew plc Vericel Corporation Osiris Therapeutics Inc. (acquired by Smith & Nephew in 2019) Histogenics Corporation Anika Therapeutics Inc. Arthrex Inc. B. Braun Melsungen AG Stryker Corporation CONMED Corporation Orthocell Limited RTI Surgical Holdings Inc. MEDIPOST Co. Ltd. CellGenix GmbH Tissue Regenix Group plc CollPlant Biotechnologies Ltd. ISTO Technologies Inc. MTF Biologics CartiHeal Ltd Regional Analysis 1. North America: - The United States and Canada dominate the North American Cartilage Repair Market. The U.S. is the largest market globally, driven by advanced global infrastructure, high R&D investments, and significant Cartilage Repair consumption. 2. Europe: - Europe is a significant player, with major Cartilage Repair Markets in Germany, France, and the United Kingdom. The region benefits from strong regulatory frameworks, high industry standards, and a robust R&D sector. 3. Asia-Pacific: - This region is experiencing rapid growth, with countries like China and India leading the charge. Factors such as increasing industry access, growing middle-class populations, and expanding Cartilage Repair manufacturing capabilities contribute to this growth. 4. Latin America: - Brazil and Mexico are key markets in Latin America. Growth in this region is driven by rising industry needs, increasing investments in industry infrastructure, and a growing demand for affordable medications. 5. Middle East and Africa: - The Cartilage Repair Market in this region is expanding due to rising market spending, increased prevalence of diseases, and improvements in Market infrastructure, although the market is relatively smaller compared to other regions. Future Outlook The Cartilage Repair Market is poised for continued growth driven by technological advancements, expanding global market access, and increasing global industry needs. As the industry adapts to evolving challenges and seizes emerging opportunities, it is likely to see ongoing innovation and expansion, contributing significantly to global health and economic development. Buy your full report: https://www.skyquestt.com/buy-now/cartilage-repair-market

Oncology Market Rising Trends, Demand and Future Scope 2024 to 2031 Leading market research firm SkyQuest Technology Group recently released a study titled 'Oncology Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Oncology report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Oncology Market extensively demonstrates existing and upcoming opportunities, profitability, revenue growth rates, pricing, and scenarios for recent industry analysis. The research analysis on the global Oncology Market report 2024 offers a close watch on top industry rivals along with briefings on their company profiles, strategical surveys, micro as well as macro industry trends, futuristic scenarios, analysis of pricing structure, and an all-encompassing overview of the Oncology Market circumstances in the forecast period between 2024 and 2031. The global Oncology Market is a dynamic and rapidly evolving sector, encompassing the development, production, and distribution. This market is essential for improving global market and driving economic growth through innovation and industry advancements. Market Growth The Oncology Market has experienced robust growth over the past decade and is projected to continue expanding. Oncology Market size was valued at USD 286.04 billion in 2022 and is poised to grow from USD 309.3 billion in 2023 to USD 581.25 billion by 2031, growing at a CAGR of 8.2% in the forecast period (2024-2031). This growth is driven by several factors, including an aging global population, increasing prevalence of advancements in technology, and rising global expenditure. Chance to get a free sample @ https://www.skyquestt.com/sample-request/oncology-market Detailed Segmentation and Classification of the report (Market Size and Forecast - 2031, Y-o-Y growth rate, and CAGR): The Oncology Market can be segmented based on several factors, including product type, application, end-user, and distribution channel. Understanding these segments is crucial for companies looking to target specific markets and tailor their offerings to meet consumer needs. Cancer Diagnostics & Treatment Cancer Diagnostics {Tumor Biomarker Test, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization}, Cancer Treatment {Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy} Cancer Type Lung Cancer, Prostate Cancer, Colon & Rectal Cancer, Gastric Cancer, Esophageal Cancer, Liver Cancer, Breast Cancer End-Use Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Academia, Specialty Clinics Get your customized report @ https://www.skyquestt.com/speak-with-analyst/oncology-market Following are the players analyzed in the report: Roche Holding AG Novartis International AG Bristol-Myers Squibb Company Pfizer Inc. Merck & Co., Inc. AstraZeneca PLC Johnson & Johnson Sanofi S.A. Takeda Pharmaceutical Company Limited Amgen Inc. AbbVie Inc. Eli Lilly and Company Gilead Sciences, Inc. Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company) Bayer AG Biogen Inc. Daiichi Sankyo Company, Limited Astellas Pharma Inc. Eisai Co., Ltd. Teva Pharmaceutical Industries Ltd. Regional Analysis 1. North America: - The United States and Canada dominate the North American Oncology Market. The U.S. is the largest market globally, driven by advanced global infrastructure, high R&D investments, and significant Oncology consumption. 2. Europe: - Europe is a significant player, with major Oncology Markets in Germany, France, and the United Kingdom. The region benefits from strong regulatory frameworks, high industry standards, and a robust R&D sector. 3. Asia-Pacific: - This region is experiencing rapid growth, with countries like China and India leading the charge. Factors such as increasing industry access, growing middle-class populations, and expanding Oncology manufacturing capabilities contribute to this growth. 4. Latin America: - Brazil and Mexico are key markets in Latin America. Growth in this region is driven by rising industry needs, increasing investments in industry infrastructure, and a growing demand for affordable medications. 5. Middle East and Africa: - The Oncology Market in this region is expanding due to rising market spending, increased prevalence of diseases, and improvements in Market infrastructure, although the market is relatively smaller compared to other regions. Future Outlook The Oncology Market is poised for continued growth driven by technological advancements, expanding global market access, and increasing global industry needs. As the industry adapts to evolving challenges and seizes emerging opportunities, it is likely to see ongoing innovation and expansion, contributing significantly to global health and economic development. Buy your full report: https://www.skyquestt.com/buy-now/oncology-market

Drug Screening Market: Competitive Insights and Precise Outlook | 2024-2031 Drug Screening Market Overview: A lot of factors, such as geographic growth, segmentation, and market size by value and volume, are taken into account in the SkyQuest Technology Group research to provide a full and accurate analysis of the global Drug Screening market. This outstanding research study was created specifically to provide the most latest data on significant aspects of the global Drug Screening Industry. Numerous market estimates are provided in the analysis, including those for market size, output, revenue, consumption, CAGR, gross margin, price, and other critical factors. The best primary and secondary research methods and tools on the Drug Screening market were used to build it. Numerous research studies are included in it, including ones on pricing analysis, production and consumption analysis, company profile, and manufacturing cost analysis. Global Drug Screening Market size was valued at USD 8.9 billion in 2022 and is poised to grow from USD 10.37 billion in 2023 to USD 35.18 billion by 2031, growing at a CAGR of 16.5% during the forecast period (2024-2031). The competitive environment is a crucial element that every key factor needs to be aware of. The study explains the market's competitive landscape so that readers may gauge the degree of both domestic and global rivalry. Additionally, market researchers have provided summaries of each significant firm in the global Drug Screening industry, taking into consideration crucial elements including operational areas, production, and product portfolio. When analyzing the organizations in the study, significant factors including business size, market share, market growth, revenue, production volume, and profitability are also taken into account. The study report uses both qualitative and quantitative data to offer a thorough view of the market. It examines and forecasts the global market in a number of critical industries. The research provides a thorough overview of the industry by segmenting the Drug Screening market into groups based on application, end-user, and location. A thorough research of each market segment was conducted, taking into consideration current and upcoming market trends. Chance to get a free sample @ https://www.skyquestt.com/sample-request/drug-screening-market Detailed Segmentation and Classification of the report (Market Size and Forecast - 2031, Y-o-Y growth rate, and CAGR): The Drug Screening Market can be segmented based on several factors, including product type, application, end-user, and distribution channel. Understanding these segments is crucial for companies looking to target specific markets and tailor their offerings to meet consumer needs. • Product & Service o Drug Screening Services [Laboratory Testing Services, On-site Testing Services], Drug Screening Products [Analytical Instruments (By Type {Breathalyzers “Fuel-cell Breathalyzers, Semiconductor Breathalyzers, Other Breathalyzers”, Immunoassay analyzers, Chromatography instruments}, By Modality {Hand-held drug screening products, Benchtop drug screening products}, Rapid Testing Devices (Urine testing devices {Drug testing cups, Dip cards, Drug testing cassettes}, Oral fluid testing devices), Consumables {Assay kit, Sample collection devices, Calibrators and controls, Other consumables}] • Sample Type o Urine Samples, Breath Samples, Oral Fluid Samples, Hair Samples, Other Samples • Drug Type o Cannabis, Alcohol, Cocaine, Opioids, Amphetamine and Methamphetamine, Other Drugs • End User o Drug Testing Laboratories, Workplaces, Criminal Justice Systems and Law Enforcement Agencies, Hospitals, Drug Treatment Centers, Individual Users, Pain Management Centers, Schools and Colleges, Other End Users Get your Customized report @ https://www.skyquestt.com/speak-with-analyst/drug-screening-market Following are the players analyzed in the report: • Quest Diagnostics (US) • Abbott (US) • OraSure Technologies Inc. (US) • Alfa Scientific Designs Inc. (US) • Thermo Fisher Scientific, Inc. (US) • Drägerwerk AG & Co. KGaA (Germany) • Lifeloc Technologies, Inc. (US) • MPD Inc. (US) • Omega Laboratories, Inc. (US) • Premier Biotech, Inc. (US) • Psychemedics Corporation (US) • F. Hoffmann-La Roche Ltd. (Switzerland) • Shimadzu Corporation (Japan) • Siemens Healthineers AG (Germany) • American Bio Medica Corporation (US) • ACM Global Laboratories (US) • CareHealth America Corp. (US) • Clinical Reference Laboratory, Inc. (US) • Intoximeters (US) • Sciteck, Inc. (US) • AccuSourceHR, Inc. (US) • Cordant Health Solutions (US) • Intoxalock (US) • Millennium Health (US) • AdvaCare Pharma (US) Motives for purchasing this report- - A full understanding of customer experiences, upcoming trends, and growth drivers may be obtained by market category analysis. -Drug Screening Market participants will be able to quickly decide on their course of action in order to achieve a competitive advantage thanks to the essential information provided in this area. The factors affecting the sales prospect are carefully examined by SkyQuest Technology Group across several important categories. - Analysing market categories can provide detailed insights into consumer experiences, upcoming trends, and growth-promoting factors. A thorough analysis of market manufacturing trends is a crucial component of the study. -These observations offer crucial information on the ways in which market participants are reacting to the most recent developments that are oversaturating the market. -An in-depth analysis of the numerous organic Buy your full Market Report now: https://www.skyquestt.com/buy-now/drug-screening-market FAQs: 1. What are the main vendors' points of strength and weakness? 2. What are the primary business plans of the leading important players for the near future? 3. What will the market size and growth rate be for Drug Screening in the upcoming year? 4. Which prevailing global trends are affecting the Drug Screening market shares of the leading regions? What effect does Covid19 have on the Industry right now?

Global Population Health Management Market size was valued at USD 33.49 Billion in 2022 poised to grow from USD 40.18 Billion in 2023 to USD 171.94 Billion by 2031, growing at a CAGR of 19.93% in the forecast period (2024-2031). The competitive environment is a crucial element that every key factor needs to be aware of. The study explains the market's competitive landscape so that readers may gauge the degree of both domestic and global rivalry. Additionally, market researchers have provided summaries of each significant firm in the global Population Health Management industry, taking into consideration crucial elements including operational areas, production, and product portfolio. When analyzing the organizations in the study, significant factors including business size, market share, market growth, revenue, production volume, and profitability are also taken into account. The study report uses both qualitative and quantitative data to offer a thorough view of the market. It examines and forecasts the global market in a number of critical industries. The research provides a thorough overview of the industry by segmenting the Population Health Management market into groups based on application, end-user, and location. A thorough research of each market segment was conducted, taking into consideration current and upcoming market trends. Chance to get a free sample @ https://www.skyquestt.com/sample-request/population-health-management-market

I soprusi contro i palestinesi dei territori occupati non sono inflitti esclusivamente per mezzo dell' esercito israeliano, bensì anche negando ad essi l' utilizzo di un copioso giacimento di gas situato a poca distanza ( 36 km ) dalla costa di Gaza. A febbraio l' ENI ha firmato un accordo, altrettanto hanno fatto una compagnia inglese ed una israeliana, con il ministero dell' energia dello Stato sionista che gli consente di effettuare delle attività di esplorazione nelle acque territoriali antistanti Gaza. Come accade da settant'anni, Israele si permette bellamente di disporre dei beni palestinesi come se fossero i propri. Attendersi dalla nostra ENI di rifiutarsi di mercanteggiare con un usurpatore sarebbe peccare di dabbenaggine. Certo è che agire così da parte dell' ENI è come affiancarsi all' esercito israeliano per arrecare ulteriori sofferenze al popolo palestinese. Nulla da dire la presidente del Consiglio che un giorno ad un comizio si compiacque di dirsi ad alta voce " sono una mamma, sono cristiana " ? Il 6 febbraio di quest' anno lo studio legale statunitense Foley Hoag Lip ha inviato alla direzione dell' ENI, per conto di quattro associazioni arabe, un avviso con il quale si chiedeva di non intraprendere alcuna attività esplorativa dacché l' area marittima ad essa assegnata rientra sotto la giurisdizione di Gaza. La richiesta era sostenuta dalle disposizioni sul diritto del mare dell' ONU del 1982, di cui era firmataria l' autorità palestinese. Un florilegio di Risoluzioni ONU sono state deliberate e ad ognuna di esse lo Stato sionista non vi ha degnato che il suo disprezzo. Anni e anni di soprusi, violenze ai danni di uomini, giovinetti, bimbi, donne, vecchi...e se accade che da parte palestinese si reagisca con asprezza, con veemenza ...allora i palestinesi si meritano la gogna .

Global Artificial Intelligence in Healthcare Market size was valued at USD 14.09 billion in 2022 and is poised to grow from USD 19.47 billion in 2023 to USD 259.11 billion by 2031, growing at a CAGR of 38.2% during the forecast period (2024-2031). The competitive environment is a crucial element that every key factor needs to be aware of. The study explains the market's competitive landscape so that readers may gauge the degree of both domestic and global rivalry. Additionally, market researchers have provided summaries of each significant firm in the global Artificial Intelligence (AI) in Healthcare industry, taking into consideration crucial elements including operational areas, production, and product portfolio. When analyzing the organizations in the study, significant factors including business size, market share, market growth, revenue, production volume, and profitability are also taken into account. The study report uses both qualitative and quantitative data to offer a thorough view of the market. Chance to get a free sample @ https://www.skyquestt.com/sample-request/artificial-intelligence-in-healthcare-market

CONTINUIAMO A FAR MATURARE LE COSCIENZE. 1’ Carta di Siena. I sottoscritti Medici ed Odontoiatri hanno prestato solenne Giuramento di rispettare il Codice Deontologico e i principi di perizia, prudenza, diligenza, indipendenza e responsabilità alla base della nostra professione. Constatano con molta amarezza che il Presidente nazionale della FNOMCeO, dott Filippo Anelli, e LA MAGGIORANZA DEI Presidenti provinciali degli Ordini hanno voltato le spalle al Codice Deontologico obbedendo agli ordini della politica. Come Organo Sussidiario dello Stato avevano il dovere di informare il Governo che la strada imboccata degli obblighi non aveva il minimo presupposto scientifico (DAL "PROIBIRE" LE AUTOPSIE AL VACCINARE I GIOVANI, LE DONNE IN GRAVlDANZA ED I GUARITI ved.foglietto illustrativo di tutti i farmaci vaccinali genici, nonché le precisazioni a proposito di EMA del 18/10/2023 ed AIFA del 19/07/2024, ma anche l' obiettivo della campagna vaccinale ministeriale 2023/2024 come da circolare ministeriale del 27/09/2023 seguente a quella del 14/08/2023). Per non dire di quanto documentato nel bollettino ufficiale del Centers for Disease Control (CDC) and Prevention USA del 30/7/2021 è dichiarato in TV dalla direttrice CDC sin dall’ 8/8/2021 : “ ciò che essi (i vaccini) non possono fare in nessun modo e’ prevenire la trasmissione. Gli Ordini provinciali si sono piegati a direttive del governo e della FNOMCeO assurde e prive di qualsivoglia supporto scientifico, come i protocolli di Tachipirina e vigile attesa e l’obbligo di vaccinazione anche per i guariti dalla malattia, tanto più in presenza di un trattamento genico che l' ISS riconosceva come vaccino solo il 22/04/2022. Gli stessi colleghi che hanno pesantemente colpito Medici virtuosi e fedeli al Giuramento di Ippocrate, ora si ripresentano. E’ nostro dovere etico il poter disconoscere il ruolo dei colleghi che si ripresentano dopo tutte queste violazioni e imposizioni non giustificabili. il testo è stato firmato da Atticciati, Barbaro, Bellavite , Borgogno, Citro, Donzelli, Iannetti , Gabrielli, Giovanardi ,Miedico, Orlandini, Pietrangeli, Romani, Raffaelli,Sanvenero, Stramezzi, Szumsky,Tolentinati,Turrini. Siena 18/9/2024. Le adesioni con Nome Cognome ed Ordine di appartenenza possano essere inviate ai seguenti e-mail : daniele.giovanardi50@libero.it annasan144@gmail.com Con preghiera della massima diffusione.

E’ morta l’étoile nera Michaela DePrince: la ballerina che seppe volare dalla guerra civile in Sierra Leone fino al firmamento della danza. 29 Anni!!! Rimasta orfana durante il conflitto, poi adottata negli Usa, era riuscita a imporsi in un mondo difficile per i danzatori di colore. La collaborazione con Beyoncé, Madonna stregata dalla sua biografia. https://www.repubblica.it/esteri/2024/09/14/news/michaela_deprince_ballerina_nera_morta_sierra_leone-423500299/amp/

Cronaca Open Arms, è in corso la requisitoria. Salvini: “Difendere i confini non è reato”. Pm: “In mare vanno salvati tutti. La nave non è posto sicuro” Open Arms, è in corso la requisitoria. Salvini: “Difendere i confini non è reato”. Pm: “In mare vanno salvati tutti. La nave non è posto sicuro” di F. Q. | 14 Settembre 2024 Matteo Salvini parla di “processo politico”. Il sostituto procuratore di Palermo Calogero Ferrara in aula ha spiegato perché nell’agosto 2019 l’allora ministro dell’Interno non avrebbe potuto bloccare 147 migranti per 19 giorni a bordo della nave dell’ong spagnola Open Arms. È in corso nell’aula bunker del carcere Pagliarelli, nel capoluogo siciliano, la requisitoria dei pm del processo al segretario nazionale della Lega, imputato con le accuse di sequestro di persona e rifiuto di atti d’ufficio per avere impedito lo sbarco, cinque anni fa, di 147 migranti che erano stati soccorsi dalla ong e che lasciarono l’imbarcazione solo dopo l’interno della Procura di Agrigento. L’accusa – la procuratrice aggiunta Marzia Sabella e i sostituti Geri Ferrara e Giorgia Righi – ha ricostruito il quadro giuridico nazionale e sovranazionale di quella fase, poi si è addentrata negli aspetti della specifica vicenda, quindi formulerà alla Corte la richiesta della pena per i reati contestati a Salvini, che all’epoca era ministro degli Interni. “Oggi a Palermo la pubblica accusa farà le sue richieste al processo che mi vede imputato per sequestro di persona – ha scritto sui social il vicepremier e leader della Lega -. Rischio fino a quindici anni di carcere per aver mantenuto la parola data agli elettori. Rifarei tutto: la difesa dei confini dai clandestini non è reato. Avanti tutta, senza paura”. Questa vicenda, ha aggiunto Salvini, “è una responsabilità politica della sinistra, che ha deciso di vendicarsi del sottoscritto mandandomi a processo. Una mossa disperata, di chi non sa vincere nelle urne e allora prova a eliminare i rivali per via giudiziaria. Un film già visto con Silvio Berlusconi e che stiamo vedendo – per certi aspetti – perfino con Donald Trump”. “La Lega ha già previsto per i prossimi due fine settimana la mobilitazione in centinaia di città italiane – con tanto di raccolta di firme – per sostenere che il processo di Palermo non è processo al segretario della Lega o all’ex ministro, ma un processo all’Italia e alla coerenza di chi ha fatto quello che aveva promesso”, ha detto il ministro dei Trasporti. “Questo è un processo politico? È pacifico che qui di atto politico non c’è nulla – ha detto in aula il sostituto procuratore Geri Ferrara durante la requisitoria -. Sono stati compiuti atti amministrativi, il rilascio di un pos è un atto amministrativo, gli atti politici sono caratterizzati da requisiti ben precisi”. “La persona in mare è da salvare – ha proseguito il magistrato, ed è irrilevante la sua classificazione: migrante, componente di un equipaggio, passeggero. Per il diritto internazionale della convenzione Sar anche un trafficante di essere umani o un terrorista va salvato poi se è il caso la giustizia fa il suo corso“. “E’ solo la terraferma a essere un pos, cioè il Place of Safety, in altre parole il posto più sicuro. E questo lo ha ribadito anche la Corte di cassazione”, ha spiegato Ferrara. “Normalmente il Pos è il porto più vicino, però questo è stato modificato nel corso degli anni. Allora dobbiamo rispondere a due domande: la nave di salvataggio può essere considerata un luogo sicuro? Come è stato rappresentato in questo processo. La risoluzione Msc dice che la nave non viene considerata un luogo in sicurezza, anche se è luogo temporaneo di sicurezza, e dovrebbe essere sollevata. Pertanto la nave può esser considerato solo un Pos temporaneo“. E aggiunge: “Che la nave non sia un luogo sicuro è un principio consolidato. Anche le navi ad hoc per effettuare il salvataggio devono avere dei requisiti ben precisi. Quindi, solo la terraferma può essere un Pos e questo lo ha ribadito anche la Cassazione”. E anche qui vanno fatti alcuni distinguo: “Non tutti i Paesi possono essere considerati un porto sicuro – ha spiegato anche Ferrara -, perché non in tutti i Paesi vigono le regole democratiche e il rispetto dei diritti umani. La Libia e la Tunisia non sono Paesi in cui si può applicare un pos”. “Lo dice anche l’attuale ministro degli Interni Matteo Piantedosi che nella sua testimonianza ha riferito che ‘i centri in Libia sono sicuramente centri illegali, mai abbiamo consegnato delle persone ai libici'”, ha affermato il sostituto procuratore. Aggiungendo: “Lo sbarco in un luogo sicuro è un obbligo di risultato”. Di conseguenza i migranti a bordo delle navi “prima si fanno scendere e poi si redistribuiscono, altrimenti si rischia di fare politica su persone che stanno soffrendo”. Il punto attorno al quale ruota il processo è la paternità della decisione di non far sbarcare i migranti. Secondo la Procura sulla questione non ci sono dubbi: “Quando Salvini diventa ministro dell’Interno le decisioni sulla gestione degli sbarchi e del rilascio dei pos vengono spostate dal Dipartimento libertà civili e immigrazione all’ufficio di gabinetto del ministro e in particolare è il ministro a decidere. Questo è l’elemento chiave“, ha proseguito il sostituto procuratore. “Ce lo confermano gli ex ministri Trenta, Di Maio, Lamorgese, l’ex premier Conte, persino il ministro Piantedosi, seppur cercando di annacquare l’obbligo, che la responsabilità di emettere il Place of Safety era del ministro Salvini – ha aggiunto Ferrara -. Lo stesso Salvini lo ammette quando dice che avrebbe firmato il pos se non fosse intervenuta la sentenza del Tar”. “E’ di intuitiva evidenza che il pm sta procedendo a una requisitoria contro il decreto sicurezza bis – ha risposto durante una pausa della requisitoria ha detto Giulia Bongiorno, legale di Salvini -, che è un atto del governo, contro la linea politica prima redistribuire e poi sbarcare. Ha proprio espresso un giudizio di grande contestazione di questa linea. Sapete perfettamente che anche in dichiarazioni pubbliche è stata una linea portata avanti da tutto il governo, anche dallo stesso premier di allora”, ha proseguito l’avvocato riferendosi a Giuseppe Conte. Fonte: https://www.ilfattoquotidiano.it/2024/09/14/open-arms-e-in-corso-la-requisitoria-salvini-difendere-i-confini-non-e-reato-pm-in-mare-vanno-salvati-tutti-la-nave-non-e-posto-sicuro/7693031/